Specialty Products Bring Distribution Challenges and Opportunities

Published Online: Tuesday, August 23, 2011
Specialty products now represent a $100 billion industry. At CBI’s 2nd Annual Forum on Strategic Distribution Planning for Specialty Products, Gina Clarke, Chief Marketing Officer, AmerisourceBergen, offers a snapshot of the specialty market as well as the segments that are poised for growth—those therapeutic areas that have achieved the greatest commercial success over the past five years.

This September 22–23, attendees come together in Philadelphia to discuss strategies that will ensure pull through and increase product usage:
  • Examine underlying reasons in your product that influence distribution strategies for specialty products. Learn more, click here.
  • Discuss factors that drive the choice to have an open, limited or closed distribution network. Ensure your edge, click here.
The complex distribution of specialty pharmaceuticals dominates the responsibilities of many senior-level executives, such as those in trade and distribution, commercial operations, and marketing. With a strong agenda filled with practical strategies, Strategic Distribution Planning for Specialty Products offers valuable insight on trends and tactics to ensure access, use and reimbursement of this growing market segment.
Latest Articles
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
As a result of implementation difficulties, the FDA announced that it will extend the pharmacy certification deadline for the clozapine risk evaluation and mitigation strategy program.
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Latest Issues